Patients with HIV had similar treatment outcomes to patients without HIV when treated for mpox with an antiviral drug called tecovirimat, according to a new study.
Nearly 90% of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.
Big Red Ventures (BRV), Cornell’s early-stage venture capital fund, showcased the student-run portfolio and highlighted 2022-23 investments during the Annual Meeting on April 20 at Cornell Tech.
The first-year class of students in the Milstein Program in Technology and Humanity are finishing up their community projects and looking forward to their summer in New York City.
The Yang-Tan WorkABILITY Incubator, recently launched through the ILR School’s Center for Applied Research on Work, will support innovative applied research projects and collaborations.
Targeting part of a key antiviral pathway may one day offer a new therapeutic approach to deterring or delaying cognitive decline, according to preclinical research led by Weill Cornell Medicine scientists.
A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial.
